Kenneth Galbraith insider trades

Open-market stock purchases and sales by Kenneth Galbraith, Chair & CEO at Zymeworks Inc, from SEC Form 4 filings since Jun 3, 2013.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -74%.

Recent trades

DateStockTradeValue
Jan 12, 2026ZYME Zymeworks IncSold$690K
Jan 12, 2026ZYME Zymeworks IncBought (not open market)—
Jan 12, 2026ZYME Zymeworks IncBought (not open market)—
Jan 12, 2026ZYME Zymeworks IncBought (not open market)—
Jan 12, 2026ZYME Zymeworks IncBought (not open market)—
Jan 5, 2026ZYME Zymeworks IncSold$795K
Jan 5, 2026ZYME Zymeworks IncBought (not open market)—
Jan 5, 2026ZYME Zymeworks IncBought (not open market)—
Jan 5, 2026ZYME Zymeworks IncSold$569K
Dec 22, 2025ZYME Zymeworks IncSold$1.3M
Dec 22, 2025ZYME Zymeworks IncBought (not open market)—

Companies traded

  • ZYME Zymeworks Inc: 8 sales, last Jan 12, 2026
  • MGNX Macrogenics Inc: 1 buy, 2 sales, last May 13, 2021
  • NONE Celator Pharmaceuticals Inc: other filings, last Jun 3, 2013

Get free alerts when Kenneth Galbraith files a new trade →